Buntanetap for Alzheimer's Disease

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2 & 3

Waitlist Available

Sponsor: Annovis Bio Inc.

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial tests buntanetap, a medication, on people with mild to moderate Alzheimer's disease. It aims to find out if different doses of the medication are effective and safe. Participants will take the medication daily for a few months, and their progress will be monitored through various assessments.

Eligibility Criteria

This trial is for people aged 55-85 with mild to moderate Alzheimer's, as per NIA criteria. They must have a study partner, be in good health without diseases affecting the study, and not at risk of self-harm. Women of childbearing age need a negative pregnancy test and agree to contraception; men must also agree to contraceptive measures.

Treatment Details

The trial tests Buntanetap's effectiveness and safety against a placebo in those with Alzheimer's over 12 weeks at home. Participants will undergo screening for up to 42 days before treatment starts, followed by four clinic visits and one phone call over approximately five months.

4Treatment groups

Experimental Treatment

Placebo Group

Group I: 7.5mg Buntanetap/PosiphenExperimental Treatment1 Intervention

Buntanetap/Posiphen 7.5mg oral capsule with daily administration for a period of 12 weeks

Group II: 30mg Buntanetap/PosiphenExperimental Treatment1 Intervention

Buntanetap/Posiphen 30mg oral capsule with daily administration for a period of 12 weeks

Group III: 15mg Buntanetap/PosiphenExperimental Treatment1 Intervention

Buntanetap/Posiphen 15mg oral capsule with daily administration for a period of 12 weeks

Group IV: PlaceboPlacebo Group1 Intervention

Placebo oral capsule with daily administration for a period of 12 weeks